Table 4 overall incidence rate of adverse effects
| Â | Pooled results | 95% CI | I2 |
|---|---|---|---|
Any grades AEs | |||
 Neutropenia | 80% | 68–89% | 93% |
 Thrombocytopenia | 61% | 49–73% | 94% |
 Anemia | 68% | 54–80% | 94% |
 AST increased | 28% | 18–43% | 92% |
 ALT increased | 30% | 26–34% | 39% |
 Serum creatine increased | 14% | 8–24% | 82% |
 APTT prolonged | 56% | 31–79% | 94% |
 Fibrinogen decreased | 13% | 6–22% | 72% |
 Serum creatine increased | 14% | 8–24% | 82% |
≥3 grade AEs | |||
 Neutropenia | 60% | 49–70% | 94% |
 Thrombocytopenia | 33% | 27–40% | 83% |
 Anemia | 32% | 25–40% | 88% |
 AST increased | 6% | 3–10% | 51% |
 ALT increased | 2% | 1–3% | 0% |
 Serum creatine increased | 1% | 0–2% | 0% |
 APTT prolonged | 4% | 1–8% | 0% |